Latest News and Press Releases
Want to stay updated on the latest news?
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 28, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises bluebird bio, Inc....
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 13, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises bluebird bio, Inc. ("bluebird"...
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises bluebird bio, Inc. ("bluebird"...
-
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
-
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises bluebird bio, Inc. ("bluebird"...
-
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
-
BLUE Lawsuit: Robbins LLP Reminds Investors of bluebird bio, Inc. of Pending Lead Plaintiff Deadline
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
-
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
-
Robbins LLP is Investigating the Allegations that Bluebird Bio, Inc. (BLUE) Overstated the Clinical and/or Commercial Prospects of its Drug
-
LOS ANGELES, April 13, 2021 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of BlueBird Bio, Inc. (NASDAQ: BLUE) investors that...